Cytomed Therapeutics gets Nasdaq notice for breaching $1 minimum bid price rule
GDTC•Cytomed Therapeutics received a Nasdaq notice after its stock closed below $1 for 30 consecutive business days. It has until April 5, 2027, to meet the rule by maintaining a closing bid of at least $1 for 10 straight sessions.
1. Compliance deadline
Cytomed Therapeutics has until April 5, 2027, to regain compliance with Nasdaq’s minimum bid-price rule by holding a closing bid price of at least $1 for 10 straight sessions. Failure to meet the deadline could lead to delisting risk, though an additional 180-day extension may be available; a reverse stock split is a potential remedy during a second compliance period.
